Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment

Executive Summary

CMS aims at “retiring” the floor hemoglobin level of 10 g/dL and lowering the target upper level to 11 g/dL in its proposed rule for the Medicare Part B prospective payment system for treatment of end-stage renal disease, a move that could apply more pressure to Amgen’s erythropoiesis-stimulating agents franchise.
Advertisement

Related Content

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point
ESRD Market Snapshot: The Price Has To Be Right
Groups Call On CMS To Maintain Floor Hemoglobin Target For ESRD Payment
Groups Call On CMS To Maintain Floor Hemoglobin Target For ESRD Payment
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Medicare Response To ESA "Overuse" In CKD Will Await Impact Of Bundled Payments, CMS Says
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach

Topics

Advertisement
UsernamePublicRestriction

Register

PS053578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel